Pyxis Oncology (NASDAQ:PYXS) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Pyxis Oncology (NASDAQ:PYXS) from a hold rating to a sell rating in a research report report published on Sunday morning.

PYXS has been the topic of a number of other research reports. HC Wainwright increased their price target on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Royal Bank Of Canada dropped their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Stephens increased their target price on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $7.20.

Pyxis Oncology Price Performance

PYXS opened at $1.62 on Friday. The firm has a 50 day simple moving average of $1.54 and a 200 day simple moving average of $2.51. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The company has a market cap of $100.86 million, a price-to-earnings ratio of -1.01 and a beta of 1.45.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the business. Laurion Capital Management LP raised its stake in shares of Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after acquiring an additional 1,170,505 shares during the last quarter. Atle Fund Management AB acquired a new position in shares of Pyxis Oncology during the fourth quarter worth $710,000. Bank of America Corp DE grew its stake in shares of Pyxis Oncology by 2,690.9% in the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares during the last quarter. Longaeva Partners L.P. acquired a new stake in Pyxis Oncology in the third quarter valued at $1,117,000. Finally, Jane Street Group LLC increased its holdings in Pyxis Oncology by 158.8% in the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after purchasing an additional 482,310 shares during the period. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.